Stopping tirzepatide is the part of the GLP-1 story that doesn’t fit into a before-and-after photo. The clearest evidence comes from SURMOUNT-4 (Aronne et al., JAMA, 2024), a randomized withdrawal trial funded by Eli Lilly. Stage one: 783 adults with obesity or overweight, without diabetes, received tirzepatide for 36 weeks. The 670 participants who reached randomization had lost an average of 20.9% of their starting body weight. Stage two: Participants were randomized to continue tirzepatide or switch to placebo for another 52 weeks. The results: Continued tirzepatide: another 5.5% weight reduction. Switched to placebo: 14% weight regain. 89.5% of participants continuing treatment maintained at least 80% of their initial weight loss. Only 16.6% of the placebo group maintained that same threshold. Here’s what people overlook. At week 88, the placebo group was still approximately 9.9% below its original weight. So no, everyone didn’t simply regain everything. But substantial weight regain was common. What the trial didn’t establish: Whether gradual tapering reduces rebound weight gain. How resistance training and dietary interventions might influence weight maintenance. How much of the regained weight consisted of fat versus lean tissue. The takeaway? Tirzepatide isn’t failing when weight returns after discontinuation. Obesity is a chronic condition, and the biological mechanisms driving appetite and weight regulation don’t necessarily disappear because someone lost weight. These medications may be better understood as long-term metabolic therapies rather than temporary weight-loss interventions. That’s an important distinction when discussing expectations, treatment duration, and long-term outcomes. #Tirzepatide #GLP1 #MetabolicHealth #WeightLoss #ObesityResearch #Biohacking #ClinicalResearch

FLGR-242 has likely been the most controversial compound introduced into the grey market, at least in the time I’ve been on X. For better or worse, it has drawn massive attention, interest, and quite literally an army of people hoping it fails, mostly for four main reasons: -Disdain for Jay Campbell. -How it was promoted on social media by BLL affiliates or general fans of the brand. -The belief that if there had been any real progress on myostatin inhibition, every pro bodybuilder would already be using it-or Big Pharma would have moved on it. -The price. It’s subjective based on individual needs, and with sales plus the ability to split vials (also with the former Slim-Assist product), most people spent far less than the advertised figures. On the first point, Jay and his team behind the scenes have been nothing but helpful and mentoring to me. Honestly, every vendor I represent-from Elite to Plugs to BLL-has had the man at the top help me in my journey more than I can describe. Everyone should be rooting for effective myostatin inhibition to become a reality, while also understanding the legitimate concerns that come with it, just like with most other compounds used in this space. If this approach is ever refined, the core idea remains: when used carefully and monitored, it could be paired with other enhancements (AAS, HGH, testosterone) so you could potentially run lower doses of the AAS side and still achieve results that previously required higher amounts. That matters for reduced side effects overall while still supporting more anabolism. The logic is that easing the myostatin “brake” makes the job of AAS or other anabolic compounds a bit easier. Most people can agree the concept is sound. The lack of independent data on FLGR-242 itself is a completely legitimate concern-and one I understand. At the same time, it seems unlikely the team would push this far with patents and related development if they didn’t have some degree of confidence in the approach. Continuing to apply the same albumin-binding concept across additional products also suggests they see real value in the underlying technology rather than treating this as a one-off gamble. It is genuinely one of the more exciting compounds to emerge in our space. Unfortunately, it took heavy criticism on X partly because some promoters claimed it would replace steroids. I’ve never said that, never thought that, and that kind of messaging sets marketing back significantly. I’ve consistently encouraged anyone considering the cost to make sure their foundation is solid first-ideally with a testosterone base and, in my view, HGH as a strong synergistic addition to the stack. What FLGR-242 actually is, and how it fits the idea above FLGR-242 is a research-chemical product marketed as an engineered follistatin analog. BLL describe it as a fragmented/modified version of follistatin-344 (based on an activin-sparing FS I-I-type isoform) fused to an albumin-binding construct. The claimed goals are selective myostatin (GDF-8) neutralization with reduced activin binding, plus a much longer circulating half-life (advertised around 19 days) via albumin hitchhiking so that dosing can be less frequent than with unmodified follistatin. The underlying biology is real and well-established. Myostatin is a key natural brake on muscle growth; neutralizing it (or follistatin’s ability to trap it) increases muscle mass and strength in animal models and in limited primate/gene-therapy human work with related follistatin approaches. Activin-sparing designs have been studied precisely to try to retain the muscle effect while dialing down broader TGF family interference. Albumin-binding tails are a proven half-life extension strategy used in approved drugs. That said, FLGR-242 itself has no published sequence, no independent analytical characterization in the literature, and no registered human clinical trials. All performance and safety claims currently come from the sellers, affiliated anecdotes, and user reports rather than peer-reviewed data on this specific molecule. It is sold for research use only. My core framing still holds: if a selective, longer-acting myostatin brake-easer works as intended and is used alongside a solid testosterone base (and ideally HGH), it could theoretically amplify the return on other anabolic tools and let people run them more conservatively. That synergy idea is exactly why the concept is interesting to people who already optimize hormones and training. It is not a steroid replacement-nor does it need to be for it to have value. It is another potential lever on the muscle-growth pathway that, if the engineering holds up, pairs with rather than substitutes for the compounds most users already rely on. As with anything in this space, the lack of controlled human data on this exact construct means individual results, safety, and long-term effects remain uncertain. People who choose to explore it generally do so with the understanding that they are operating ahead of published evidence, with source quality, bloodwork, and fundamentals (training, nutrition, and hormonal base) mattering more than the compound itself. For those already dialed in and willing to accept the grey-market trade-offs, it remains one of the more conceptually promising new tools that has appeared in recent years. I am still a supporter, a big fan, and not only with FLGR-242, I wish success to Mid-35, and many others in the space to create new avenues that people have the option to test out. My personal experience with FLGR has been nothing short of great, and I believe is one of the closest things we the public can try out in the myostatin niche, that can give us lab rats some fun and unique progress in our journey.